ClinicalTrials.gg
WithdrawnNCT04239014DUETTEUpdated Mar 10, 2021

A Study to Evaluate the Effectiveness and Tolerability of a Second Maintenance Treatment in Participants With Ovarian Cancer, Who Have Previously Received Polyadenosine 5'Diphosphoribose [Poly (ADP Ribose)] Polymerase Inhibitor (PARPi) Treatment.

A Phase 2 interventional study of Olaparib and Ceralasertib in Ovarian Cancer, sponsored by AstraZeneca. Withdrawn at 26 sites in 4 countries. Open to female participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2021-03-10.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Why this study was withdrawn
Sponsor made the decision to terminate the DUETTE study based on the interim analysis of the VIOLETTE study (NCT03330847) investigating the combination of ceralasertib and Olaparib, where study closure was recommended due to insufficient efficacy.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 130 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 69 studies testing olaparib in Ovarian Neoplasms — 13 open to participants now, 26 under way, 9 of them phase 3. olaparib · Ovarian Neoplasms.

Enrollment
65th of 69
0 · median 97
Started
2020
with 5 others
Phase 2
32 of 69
7 open now
Registered
42nd of 69
by date
Lead sponsor
21 of 69
AstraZeneca

Among the 69 studies testing olaparib in Ovarian Neoplasms, this one is the 65th largest by enrollment, is one of 6 that started in 2020, is one of 32 in phase 2, and was the 42nd registered.

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 792 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

13 of the 69 studies testing olaparib in Ovarian Neoplasms are open now, in 8 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About olaparib

olaparib: first FDA approval 2014 (LYNPARZA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 605 Ovarian Neoplasms studies recruiting now, 442 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years to 130 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies testing olaparib in Ovarian Neoplasms, or all of them as a file.
02

Study summary

To investigate the effectiveness and tolerability of a second maintenance treatment in participants with platinum-sensitivity relapsed (PSR) epithelial ovarian cancer, who have previously received PARPi maintenance treatment and who have benefit (complete response [CR] or partial response [PR]) or stable disease (SD) from further platinum based chemotherapy.

Read the detailed description

This is a Phase II, randomised, multicentre study to investigate the efficacy and tolerability of a second maintenance treatment in participants with PSR epithelial ovarian cancer, who have previously received PARPi maintenance treatment and who have benefit (CR or PR) or SD from further platinum based chemotherapy.

Participants will be recruited globally from approximately 120 study sites in the USA, Canada, Middle East and Europe.

Approximately 192 participants fulfilling all of the inclusion criteria and none of the exclusion criteria will be randomised in a 1:1:1 ratio to the following 3 treatment arms (64 participants per arm):

  • Arm 1 (ceralasertib+olaparib): Ceralasertib 160 mg once daily (QD) orally or per os (PO) on Days 1 to 7 plus olaparib 300 mg twice daily (BD) PO continuous (28 day cycle)
  • Arm 2 (olaparib monotherapy): Olaparib 300 mg BD PO daily continuous
  • Arm 3 (placebo): Placebo to match olaparib BD PO daily continuous

The olaparib and placebo arms will be double blinded, whereas the ceralasertib+olaparib arm will be open label. It is expected that approximately 320 participants will be screened.

The study achieved First Subject In date, but enrollment equals 0 as 7 participants have signed the Informed Consent Form (ICF) and were later screen failed.

03

Conditions studied

  • Ovarian Cancer

Browse trials for

Keywords

  • Platinum Sensitive Relapsed Epithelial Ovarian Cancer
  • Polyadenosine 5'diphosphoribose (poly [ADP ribose]) polymerase inhibitor (PARPi)
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Capable of providing signed , which includes compliance with the requirements and restrictions listed in the ICF and in the Clinical Study Protocol (CSP).
  • Provision of signed and dated, written ICF prior to any mandatory study specific procedures, sampling, and analyses.
  • Female ≥18 years of age at the time of signing the ICF.
  • performance status 0 to 1 within 28 days of randomization.
  • Participants with confirmed diagnosis of high grade epithelial ovarian cancer (including primary peritoneal and/or fallopian tube cancer), with disease relapse on or after completion of PARPi maintenance therapy and who have not received any intervening systemic treatment since discontinuation of PARPi (this excludes the platinum based chemotherapy received during Screening Part 1 of this study).
  • A minimum of 6 months of prior PARPi treatment received in the maintenance setting for PSR ovarian cancer (a minimum of 12 months is required if the participant received PARPi maintenance following chemotherapy). If the prior PARPi used was olaparib then participants must have received treatment without significant toxicity or the need for a permanent dose reduction.
  • Disease relapse in the second line (first relapse) or third line (second relapse) setting.
  • Able to provide and consent to the collection of a contemporaneous tumor tissue and blood sample.
  • Able to provide a Formalin Fixed Paraffin Embedded archival tumour tissue block from the time of primary tumour diagnosis (taken ideally prior to receiving any systemic treatment, and definitely prior to first PARPi treatment) for prospective Breast cancer susceptibility gene (BRCA) status testing. If tumour blocks are unavailable, tissue sections are acceptable with a minimum requirement of at least 20 unstained sections on uncharged slides without cover slips. Fine needle aspirates are not acceptable.
  • Where the patient has previously been tested for germline or somatic BRCA alterations using a verified and well-validated test in line with local regulations, performed in a locally accredited laboratory (eg, College of American Pathologists/Clinical Laboratory Improvement Amendments laboratory, where available), and signed consent to provide a copy of the BRCA report.
  • Platinum-sensitive disease at the time of disease relapse, i.e, platinum-treatment free survival of greater than 6 months as defined by the Gynecological Cancer Intergroup (Wilson et al 2017).
  • For the platinum-based chemotherapy course received following pre screening (Part 1) and prior to entering the main screening (Part 2).
  • Any prior palliative radiation must have been completed at least 7 days prior to the start of study drugs, and participants must have recovered from any acute adverse effects prior to the start of study treatment.
  • Normal organ and bone marrow function measured within 28 days prior to randomization.
  • Participant is willing and able to comply with the CSP for the duration of the study including undergoing treatment and scheduled visits and examinations.
  • Participants must have a of ≥16 weeks.
  • Participants must be able to swallow tablets whole.
  • For inclusion in the optional (deoxyribonucleic acid) genetics research, study participants must fulfil the following criterion:

Provide informed consent for the genetic sampling and analyses. If a participant declines to participate in the genetics research, there will be no penalty or loss of benefit to the participant. A participant who declines genetics research participation will not be excluded from any other aspect of the main study.

  • Participant's body weight must be >30 kg.
  • or evidence of non-childbearing status for women of .
  • Women of childbearing potential and their partners, who are sexually active, must agree to the use of 2 highly effective forms of in combination from the signing of the informed consent (Screening Part 1), throughout the period of taking study treatment and for at least 6 months after the last dose of study drug(s).

Exclusion criteria

Exclusion Criteria:

  • Participants who have had drainage of their ascites during the final 2 cycles of their last chemotherapy regimen or during the period between completion of chemotherapy and first dose of study treatment.
  • Participants with current signs or symptoms of bowel obstruction, including sub-occlusive disease, related to underlying disease.
  • History of .
  • Participants with symptomatic uncontrolled .

    1. A scan to confirm the absence of brain metastases is not required.
    2. Participants whose brain metastases have been treated may participate provided they show radiographic stability. In addition, any neurologic symptoms that developed either as a result of the brain metastases or their treatment must have resolved or be stable ( [CTCAE] Grade \<2) either, without the use of , or are stable on a steroid dose of ≤10 mg/day of prednisone or its equivalent and stable on anti convulsants if required for at least 14 days prior to the start of treatment.
    3. Participants with spinal cord compression are not eligible unless considered to have received definitive treatment for this and have evidence of clinically SD for >28 days and have not received steroid treatment for at least 14 days prior to the start of study treatment.
  • History of another primary except for:

    1. Malignancy treated with curative intent and with no known active disease ≥5 years before the first dose of IP and of low potential risk for recurrence;
    2. Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease;
    3. Adequately treated carcinoma in situ without evidence of disease.
  • Major surgical procedures (as defined by the investigator) ≤28 days of beginning study treatment, or minor surgical procedures ≤7 days. No waiting period required following port a cath or other central venous access placement.
  • Persistent toxicities (≥CTCAE Grade 2) caused by previous cancer therapy, excluding alopecia and CTCAE Grade 2 peripheral neuropathy. Note: participants with signs of ongoing complications from radiation therapy are not eligible for this study.
  • Participants with myelodysplastic syndrome (MDS) /acute myeloid leukemia (AML) or with features suggestive of MDS/AML.
  • Resting indicating uncontrolled, potentially reversible cardiac conditions, as judged by the investigator, or participants with congenital long syndrome.
  • Known allergy or to any of the study drugs or any of the study drug .
  • History of allogeneic organ transplantation including previous bone marrow transplant or double umbilical cord blood transplantation.
  • History of active primary immunodeficiency.
  • Active infection including tuberculosis (TB), (known positive hepatitis B virus [HBV] surface antigen [HBsAg] result), (HCV), or (HIV) (positive HIV 1/2 antibodies). Participants with a past or resolved HBV infection are eligible. Participants positive for HCV antibody are eligible only if polymerase chain reaction is negative for HCV ribonucleic acid.
  • Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, uncontrolled cardiac arrhythmia, active interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations.
  • Current dependency on total parenteral nutrition or intravenous (iv) fluid hydration.
  • Whole blood transfusions in the last 120 days prior to entry to the study.
  • Cytotoxic chemotherapy, hormonal or non hormonal targeted therapy within 21 days of Cycle 1, Day 1 is not permitted. The participant can receive a stable dose of bisphosphonates or denosumab for bone , before and during the study as long as these were started at least 5 days prior to study treatment.
  • Participation in another clinical study with an IP during the chemotherapy course immediately prior to randomisation or during the course of the study.
  • Previous treatment with ceralasertib or other ataxia telangiectasia and Rad3-related protein, Checkpoint kinase 1 or deoxyribonucleic acid damage response inhibitor (excluding PARPi).
  • Exposure to a small molecule IP within 30 days or 5 half-lives (whichever is longer) prior to randomization. The minimum for immunotherapy and bevacizumab shall be 42 days.
  • Receipt of within 30 days prior to the first dose of study treatment.
  • Concomitant use of known strong cytochrome P450 (CYP) 3A inhibitors or moderate inhibitors. The required washout period prior to starting study treatment is 2 weeks.
  • Concomitant use of known strong CYP3A inducers or moderate CYP3A inducers. The required washout period prior to starting study treatment is 5 weeks for enzalutamide or phenobarbital and 3 weeks for other agents.
  • Involvement in the planning and/or conduct of the study (applies to Sponsor staff and/or staff at the study site).
  • Previous randomization in the present study.
  • Judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions and requirements.
  • Pregnant or lactating women.
Terms in these criteria, in plain language(27)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Arm 1 (ceralasertib+olaparib)

    Participants received ceralasertib 160 mg QD PO on Days 1 to 7 plus olaparib 300 mg BD PO continuous (28 day cycle).

    Drug: Olaparib · Drug: Ceralasertib

  • Experimental
    Arm 2 (olaparib monotherapy)

    Olaparib 300 mg BD PO daily continuous.

    Drug: Olaparib

  • Experimental
    Arm 3 (placebo)

    Placebo to match olaparib BD PO daily continuous.

    Drug: Placebo to match olaparib

Interventions

  • Olaparib 300 mg BD (2 × 150 mg tablets) continually in the olaparib monotherapy and ceralasertib+olaparib treatment arms.

    Also known as: AZD2281

  • Ceralasertib 160 mg QD (2 × 80 mg tablets) from Days 1 to 7 (inclusive) of every 28-day cycle.

    Also known as: AZD6738

  • DrugPlacebo to match olaparib

    Per olaparib

06

What researchers measure

Primary outcomes

  1. Progression free survival (PFS)

    To assess the efficacy of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo.

    Time frame: To assess from the time of randomization until the date of objective disease progression or death (by any cause in the absence of progression) or approximately up to 2.5 years.

Secondary outcomes

  1. Overall survival (OS)

    To further assess the efficacy of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo; and to assess the efficacy of maintenance ceralasertib+olaparib combination therapy compared with olaparib monotherapy.

    Time frame: To assess every 8 weeks (±7 days) for first 72 weeks following objective disease progression or treatment discontinuation and then every 12 weeks, up to approximately 2.5 years.

  2. Time to second progression

    To further assess the efficacy of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo; and to assess the efficacy of maintenance ceralasertib+olaparib combination therapy compared with olaparib monotherapy. A participant's second progression status is defined according to the local standard clinical practice and may involve any of; investigator assessment of radiological progression, cancer antigen 125 (CA 125) progression, symptomatic progression or death.

    Time frame: To assess every 8 weeks (±7 days) for first 72 weeks following objective disease progression or treatment discontinuation and then every 12 weeks, up to approximately 2.5 years.

  3. Objective response rate

    To further assess the efficacy of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo; and to assess the efficacy of maintenance ceralasertib+olaparib combination therapy compared with olaparib monotherapy.

    Time frame: At baseline, every 8 weeks for first 72 weeks, then every 12 weeks after randomization until objective disease progression or approximately up to 2.5 years.

  4. Duration of response

    To further assess the efficacy of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo; and to assess the efficacy of maintenance ceralasertib+olaparib combination therapy compared with olaparib monotherapy.

    Time frame: At baseline, every 8 weeks for first 72 weeks, then every 12 weeks after randomization until objective disease progression or approximately up to 2.5 years.

  5. Percentage change in tumour size

    To further assess the efficacy of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo.

    Time frame: At baseline, every 8 weeks for first 72 weeks, then every 12 weeks after randomization until objective disease progression or approximately up to 2.5 years.

  6. Plasma concentration data for olaparib and ceralasertib

    To evaluate the pharmacokinetic (PK) exposure of ceralasertib+olaparib combination therapy.

    Time frame: At cycle 1 Day 1 and Day 7

  7. Change from baseline in European Organisation for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC-QLQ) C30

    To assess the impact of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo on participants' symptoms, functioning, and Health-related quality of life (HRQoL). Questions are grouped into functional scales, symptom scales, a global health status / quality of life (QoL) scale, assessing additional symptoms commonly reported by cancer participants, and the financial impact of the disease. All but 2 questions are rated on a 4 point verbal rating scale: "Not at all," "A little," "Quite a bit," and "Very much." The 2 questions concerning global health status and QoL have 7 point scales with ratings ranging from "Very poor" to "Excellent." For each of the 15 domains, final scores are transformed such that they range from 0 to 100, where higher scores indicate better functioning, better QoL, or worse symptoms.

    Time frame: At Cycle1 Day 1, every 4 weeks from Cycle 1 Day 1 until treatment discontinuation, and follow-up 30 days after last dose of study medication.

  8. Change from baseline in EORTC-QLQ-OV28

    To assess the impact of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo on participants' symptoms, functioning, and HRQoL It consists of 28 items assessing abdominal/gastrointestinal symptoms (6 items), peripheral neuropathy (2 items), other chemotherapy side effects (5 items), hormonal symptoms (2 items), body image (2 items), attitudes to disease/treatment (3 items), sexuality (4 items) and 4 other single items. All questions are rated on a 4 point verbal rating scale: "Not at all," "A little," "Quite a bit," and "Very much." Final scores are transformed such that they range from 0 to 100, where higher scores indicate greater functioning, greater QoL, or greater level of symptoms.

    Time frame: At Cycle1 Day 1, every 4 weeks from Cycle 1 Day 1 until treatment discontinuation, and follow-up 30 days after last dose of study medication.

  9. Time to earliest progression by RECIST 1.1 or CA-125 or death

    Time to progression by RECIST 1.1 or CA-125 progression or death is defined as the time from randomisation to the earlier date of RECIST 1.1 or CA-125 progression or death by any cause.

    Time frame: At baseline, every 8 weeks for first 72 weeks, then every 12 weeks after randomization until objective disease progression or approximately up to 2.5 years.

Other outcomes

  1. Number of participants with adverse events (AEs)

    To assess the safety and tolerability of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo.

    Time frame: From Cycle 1 Day 1 to follow-up 30 days after the last dose of study medication.

  2. Number of participants with abnormal physical examination

    To assess the safety and tolerability of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo.

    Time frame: From Cycle 1 Day 1 to follow-up 30 days after the last dose of study medication.

  3. Number of participants with abnormal Eastern Cooperative Oncology Group (ECOG) performance status (PS)

    To assess the safety and tolerability of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo.

    Time frame: From Cycle 1 Day 1 to follow-up 30 days after the last dose of study medication.

  4. Number participants with abnormal systolic and diastolic blood pressure

    To assess the safety and tolerability of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo.

    Time frame: From Cycle 1 Day 1 to follow-up 30 days after the last dose of study medication.

  5. Number of participants with abnormal pulse

    To assess the safety and tolerability of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo.

    Time frame: From Cycle 1 Day 1 to follow-up 30 days after the last dose of study medication.

  6. Number of participants with abnormal body temperature

    To assess the safety and tolerability of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo.

    Time frame: From Cycle 1 Day 1 to follow-up 30 days after the last dose of study medication.

  7. Number of participants with abnormal electrocardiogram

    To assess the safety and tolerability of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo.

    Time frame: From Cycle 1 Day 1 to follow-up 30 days after the last dose of study medication.

  8. Number of participants with abnormal hemoglobin (Hb)

    To assess the safety and tolerability of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo.

    Time frame: From Cycle 1 Day 1 to follow-up 30 days after the last dose of study medication.

  9. Number of participants with abnormal leukocyte count

    To assess the safety and tolerability of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo.

    Time frame: From Cycle 1 Day 1 to follow-up 30 days after the last dose of study medication.

  10. Number of participants with abnormal absolute neutrophil count (ANC)

    To assess the safety and tolerability of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo.

    Time frame: From Cycle 1 Day 1 to follow-up 30 days after the last dose of study medication.

  11. Number of participants with abnormal absolute lymphocyte count

    To assess the safety and tolerability of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo.

    Time frame: From Cycle 1 Day 1 to follow-up 30 days after the last dose of study medication.

  12. Number of participants with abnormal platelet count

    To assess the safety and tolerability of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo.

    Time frame: From Cycle 1 Day 1 to follow-up 30 days after the last dose of study medication.

  13. Number of participants with abnormal mean cell volume

    To assess the safety and tolerability of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo.

    Time frame: From Cycle 1 Day 1 to follow-up 30 days after the last dose of study medication.

  14. Number of participants with abnormal serum creatinine

    To assess the safety and tolerability of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo.

    Time frame: From Cycle 1 Day 1 to follow-up 30 days after the last dose of study medication.

  15. Number of participants with abnormal serum total bilirubin

    To assess the safety and tolerability of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo.

    Time frame: From Cycle 1 Day 1 to follow-up 30 days after the last dose of study medication.

  16. Number of participants with abnormal serum alanine aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase

    To assess the safety and tolerability of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo.

    Time frame: From Cycle 1 Day 1 to follow-up 30 days after the last dose of study medication.

  17. Number of participants with abnormal serum potassium, calcium and sodium

    To assess the safety and tolerability of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo.

    Time frame: From Cycle 1 Day 1 to follow-up 30 days after the last dose of study medication.

  18. Number of participants with abnormal plasma glucose

    To assess the safety and tolerability of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo.

    Time frame: From Cycle 1 Day 1 to follow-up 30 days after the last dose of study medication.

  19. Number of participants with abnormal serum lactate dehydrogenase

    To assess the safety and tolerability of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo.

    Time frame: From Cycle 1 Day 1 to follow-up 30 days after the last dose of study medication.

  20. Number of participants with abnormal creatinine clearance

    To assess the safety and tolerability of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo.

    Time frame: From Cycle 1 Day 1 to follow-up 30 days after the last dose of study medication.

  21. Number of participants with abnormal serum urea or blood urea nitrogen

    To assess the safety and tolerability of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo.

    Time frame: From Cycle 1 Day 1 to follow-up 30 days after the last dose of study medication.

  22. Number of participants with abnormal plasma total protein

    To assess the safety and tolerability of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo.

    Time frame: From Cycle 1 Day 1 to follow-up 30 days after the last dose of study medication.

  23. Number of participants with abnormal urine Hb/erythrocytes/blood

    To assess the safety and tolerability of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo.

    Time frame: From Cycle 1 Day 1 to follow-up 30 days after the last dose of study medication.

  24. Number of participants with abnormal urine protein/albumin

    To assess the safety and tolerability of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo.

    Time frame: From Cycle 1 Day 1 to follow-up 30 days after the last dose of study medication.

  25. Number of participants with abnormal urine glucose

    To assess the safety and tolerability of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo.

    Time frame: From Cycle 1 Day 1 to follow-up 30 days after the last dose of study medication.

  26. Number of participants with abnormal urine ketones

    To assess the safety and tolerability of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo.

    Time frame: From Cycle 1 Day 1 to follow-up 30 days after the last dose of study medication.

  27. Number of participants with abnormal urine pH

    To assess the safety and tolerability of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo.

    Time frame: From Cycle 1 Day 1 to follow-up 30 days after the last dose of study medication.

  28. Number of participants with abnormal specific gravity

    To assess the safety and tolerability of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo.

    Time frame: From Cycle 1 Day 1 to follow-up 30 days after the last dose of study medication.

  29. Number of participants with abnormal urine bilirubin

    To assess the safety and tolerability of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo.

    Time frame: From Cycle 1 Day 1 to follow-up 30 days after the last dose of study medication.

  30. European quality of life 5 dimensions, 5 level

    To assess both European quality of life descriptive system and European quality of life visual analogue scale (EQ VAS). The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The participant is asked to indicate his health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the participant's health state. The EQ VAS records the participant's self-rated health on a vertical visual analogue scale, where the endpoints are labelled 'the best health you can imagine' and 'the worst health you can imagine'.

    Time frame: From Cycle 1 Day 1 to follow-up 30 days after the last dose of study medication.

  31. Patient Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)

    To assess tolerability from the participants perspective. PRO-CTCAE is an item library of symptomatic AEs experienced by patients while undergoing treatment of their cancer. PRO questionnaires completed at site visits must be completed prior to treatment administration

    Time frame: From Cycle 1 Day 1 to follow-up 30 days after the last dose of study medication.

  32. Patient global impression of severity

    To assess overall severity of participant's cancer symptoms over the past week. The item is rated using a 6 point verbal rating scale from "No Symptoms" to "Very Severe".

    Time frame: From Cycle 1 Day 1 to follow-up 30 days after the last dose of study medication.

  33. Patient global impression of change

    To assess overall change in health condition since the start of study treatment(s). The item is rated using a 7 point Likert type scale from "Much Better" to "Much Worse".

    Time frame: From Cycle 1 Day 1 to follow-up 30 days after the last dose of study medication.

  34. Patient global impression-treatment tolerability

    To asses overall bother associated with symptomatic AEs. The item is rated using a 6 point verbal scale from "Not at All" to "Very Much".

    Time frame: From Cycle 1 Day 1 to follow-up 30 days after the last dose of study medication.

  35. Patient global impression-benefit risk

    To asses the participant's perception of the overall benefits and risks of treatment. The 5 items to be assessed included overall trial experience, efficacy, side effects, convenience, and overall assessment of the benefits and harms of treatment. Items are rated on 5 or 6 point verbal rating or Likert type scales.

    Time frame: From Cycle 1 Day 1 to 12 weeks and 16 weeks of study medication.

07

Study locations

26 sites
  • Research Site
    Anchorage, Alaska 99508, United States
  • Research Site
    La Jolla, California 92093-0021, United States
  • Research Site
    Long Beach, California 90806, United States
  • Research Site
    Los Angeles, California 90048, United States
  • Research Site
    West Hollywood, California 97210, United States
  • Research Site
    Hartford, Connecticut 06106, United States
  • Research Site
    Tampa, Florida 33612, United States
  • Research Site
    Atlanta, Georgia 30342, United States
  • Research Site
    Louisville, Kentucky 40202, United States
  • Research Site
    Covington, Louisiana 70433, United States
  • Research Site
    Florham Park, New Jersey 07932, United States
  • Research Site
    Teaneck, New Jersey 07666, United States
  • Research Site
    Cleveland, Ohio 44106, United States
  • Research Site
    Oklahoma City, Oklahoma 73104, United States
  • Research Site
    Tulsa, Oklahoma 74146, United States
  • Research Site
    Portland, Oregon 97210, United States
  • Research Site
    Abington, Pennsylvania 19001, United States
  • Research Site
    Philadelphia, Pennsylvania 19104, United States
  • Research Site
    Sioux Falls, South Dakota 57105-1599, United States
  • Research Site
    Sioux Falls, South Dakota 57105, United States
  • Research Site
    Houston, Texas 77030, United States
  • Research Site
    Seattle, Washington 98104, United States
  • Research Site
    Toronto, Ontario M5G 2M9, Canada
  • Research Site
    Montreal, Quebec H3A 1A1, Canada
  • Research Site
    Napoli, 80131, Italy
  • Research Site
    Barcelona, 8035, Spain
08

References and documents

Publications

  • McMullen M, Karakasis K, Loembe B, Dean E, Parr G, Oza AM. DUETTE: a phase II randomized, multicenter study to investigate the efficacy and tolerability of a second maintenance treatment in patients with platinum-sensitive relapsed epithelial ovarian cancer, who have previously received poly(ADP-ribose) polymerase (PARP) inhibitor maintenance treatment. Int J Gynecol Cancer. 2020 Nov;30(11):1824-1828. doi: 10.1136/ijgc-2020-001694. Epub 2020 Sep 2. PubMed 32878963 ↗

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please re-refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2020 to primary completion in Jan 2021, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 21, 2020
First posted
Jan 23, 2020
StartActual
Aug 7, 2020
Primary completionActual
Jan 25, 2021
CompletionActual
Jan 25, 2021
Last update
Mar 10, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 10, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04239014
Lead sponsor
AstraZeneca
Collaborators
Parexel
Responsible party
Sponsor
First posted
Jan 23, 2020
Start date
Aug 7, 2020
Primary completion
Jan 25, 2021
Completion
Jan 25, 2021
Last update
Mar 10, 2021

Study contacts

Dr Amit Oza, MD (Lon) FRCP FRCPC
principal investigator · Princess Margaret Cancer Centre, UHN and Mt. Sinai Health System

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Olaparib · Ceralasertib

Start the discussion